2019 Annual Meeting | C76 - Assessment of Rapidly Progressive Dementias II: Infections and Autoimmune Mediated Conditions
Program Materials Program Evaluations
03:30 PM - 03:35 PM EDT | Speaker |
Introduction
Michael D. Geschwind, MD, PhD, FAAN |
03:35 PM - 04:25 PM EDT | Speaker |
Infections as Rapidly Progressive Dementia
Allen J. Aksamit, Jr., MD, FAAN |
04:25 PM - 05:15 PM EDT | Speaker |
Autoimmune Causes of Rapidly Progressive Dementia
Jeffrey M. Gelfand, MD, MAS, FAAN |
05:15 PM - 05:30 PM EDT | Speaker |
Questions and Answers
|
05:30 PM - 06:00 PM EDT | Discussion |
Continuing the Conversation
|
Michael D. Geschwind, MD, PhD, FAAN | Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Brainstorm Cell Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Walter Grubb. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Reata Pharmaceuticals, Inc.. |
Allen J. Aksamit, Jr., MD, FAAN | Dr. Aksamit has nothing to disclose. |
Jeffrey M. Gelfand, MD, MAS, FAAN | Dr. Gelfand has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Arialys. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ventyx Bio. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache: The Journal of Head and Face Pain. The institution of Dr. Gelfand has received research support from Genentech/Roche. The institution of Dr. Gelfand has received research support from Vigil Neurosciences. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has a non-compensated relationship as a Trial Steering Committee Chairperson and member with Roche / Genentech that is relevant to AAN interests or activities. |